Viewing Study NCT05039658


Ignite Creation Date: 2025-12-25 @ 12:00 AM
Ignite Modification Date: 2026-01-01 @ 3:04 PM
Study NCT ID: NCT05039658
Status: UNKNOWN
Last Update Posted: 2021-09-09
First Post: 2021-09-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module